Aldevron is excited to share an update on our partner's progress regarding their AAVCOVID vaccine program. Mass Eye and Ear's novel gene-based vaccine strategy utilizes an adeno-associated virus (AAV) vector.
AAVCOVID is being developed through an academia-industry consortium with groups within Massachusetts Eye and Ear, and Massachusetts General Hospital, both member hospitals of Mass General Brigham in Boston, the University of Pennsylvania in Philadelphia and Novartis Gene Therapies.
Preclinical data on this single-dose, room temperature-stable COVID-19 vaccine was recently released and is showing the vaccine remains potent and effective when stored at room temperature when stored up to one month.
Recently, the Bill and Melinda Gates Foundation awarded a grant up to $2.1M enabling the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 20201, marking a significant milestone in developing this novel approach.
As a manufacturing partner, Aldevron is proud to continue supporting with Harvard scientists at Mass Eye and Ear and Mass General to produce the new AAV based gene therapy approach for a potential SARS-CoV-2 vaccine.
Read the full press release here.
To learn more about this partnership, check out our original news post here.